DRUG-DRUG INTERACTION (DDI) STUDY BETWEEN THE INVESTIGATIONAL NAE INHIBITOR PEVONEDISTAT (TAK-924) AND FLUCONAZOLE OR ITRACONAZOLE IN PATIENTS WITH ADVANCED SOLID TUMORS.

被引：0
|
作者：
Faessel, H. M. [1 ]
Harvey, R. D. [2 ]
Lockhart, A. C. [3 ]
Bauer, T. M. [4 ]
Wang, L. [1 ]
Sedarati, F. [1 ]
Santillana, S. [1 ]
Nemunaitis, J. J. [5 ]
机构：
[1] Millennium Pharmaceut Inc, Cambridge, MA USA
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA
[4] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA
[5] Mary Crowley Canc Res Ctr, Dallas, TX USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-084
引用
收藏
页码：S97 / S97
页数：1
相关论文
共 50 条
  • [1] Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors
    Sarantopoulos, John
    Shapiro, Geoffrey I.
    Cohen, Roger B.
    Clark, Jeffrey W.
    Kauh, John S.
    Weiss, Glen J.
    Cleary, James M.
    Mahalingam, Devalingam
    Pickard, Michael D.
    Faessel, Helene M.
    Berger, Allison J.
    Burke, Kristine
    Mulligan, George
    Dezube, Bruce J.
    Harvey, R. Donald
    CLINICAL CANCER RESEARCH, 2016, 22 (04) : 847 - 857
  • [2] A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma
    Bhatia, Shailender
    Pavlick, Anna C.
    Boasberg, Peter
    Thompson, John A.
    Mulligan, George
    Pickard, Michael D.
    Faessel, Helene
    Dezube, Bruce J.
    Hamid, Omid
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (04) : 439 - 449
  • [3] A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma
    Shailender Bhatia
    Anna C. Pavlick
    Peter Boasberg
    John A. Thompson
    George Mulligan
    Michael D. Pickard
    Hélène Faessel
    Bruce J. Dezube
    Omid Hamid
    Investigational New Drugs, 2016, 34 : 439 - 449
  • [4] Evaluation of pharmacokinetic (PK) drug-drug interactions (DDI) between trebananib (AMG 386) and paclitaxel (PTX) in patients (pts) with advanced solid tumors.
    Diamond, Jennifer Robinson
    Agarwal, Neeraj
    Bowles, Daniel W.
    Lam, Elaine Tat
    Werner, Theresa Louise
    Wu, Benjamin
    Rasmussen, Erik
    Gamelin, Erick
    Soto, Felipe
    Friberg, Gregory R.
    Sun, Yu-Nien
    Sharma, Sunil
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors.
    Adjei, Alex A.
    LoRusso, Patricia
    Ribas, Antoni
    Sosman, Jeffrey Alan
    Pavlick, Anna C.
    Dy, Grace K.
    Zhou, Xiaofei
    Gangolli, Esha A.
    Walker, Russell M.
    Kneissl, Michelle
    Faucette, Stephanie
    Neuwirth, Rachel
    Bozon, Viviana
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors
    Wang, Ding
    Braiteh, Fadi
    Lee, James J.
    Denlinger, Crystal S.
    Shepard, Dale R.
    Chaudhary, Archana
    Lin, Yong
    Gao, Ling
    Asakiewicz, Christopher
    Nasroulah, Federico
    LoRusso, Patricia
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (04) : 727 - 733
  • [7] Absence of interaction of cabazitaxel on the pharmacokinetics of midazolam: Results of a drug-drug interaction study in patients with advanced solid tumors
    Rixe, Olivier
    Sarantopoulos, John
    Hsueh, Chung-Tsen
    Lockhart, A. Craig
    Ross, Sharona
    Agarwala, Sanjiv S.
    Zhang, Wendy
    Yin, Jian Y.
    Wack, Claudine
    Mazuir, Florent
    Gurtler, Jayne S.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [8] Lack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors
    Chow, Laura Q. M.
    Smith, David C.
    Tan, Antoinette R.
    Denlinger, Crystal S.
    Wang, Ding
    Shepard, Dale R.
    Chaudhary, Archana
    Lin, Yong
    Gao, Ling
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 433 - 441
  • [9] A drug-drug interaction study between the strong CYP3A4 inhibitor ketoconazole (keto) and ixazomib citrate (MLN9708), an investigational, orally active proteasome inhibitor, in patients with advanced solid tumors or lymphoma
    Gupta, Neeraj
    Venkatakrishnan, Karthik
    Noe, Dennis A.
    Hanley, Michael J.
    Yu, Jiang
    Bessudo, Alberto
    Sharma, Sunil
    Strother, Robert Matthew
    Shou, Yaping
    Nemunaitis, John J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] A drug-drug interaction study of capecitabine and celecoxib in patients with advanced solid malignancies.
    Ramirez, Jacqueline
    House, Larry
    Karrison, Theodore G.
    Janisch, Linda A.
    Turcich, Michelle
    Salgia, Ravi
    Ratain, Mark J.
    Sharma, Manish
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345